Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study

Authors

  • Raffaele Longo Division of Medical Oncology, “CHR Metz-Thionville”, Ars- Laquenexy, France
  • Victoire Thiebaut Division of Medical Oncology, “CHR Metz-Thionville”, Ars- Laquenexy, France
  • Pierre-Olivier Legros Division of Medical Oncology, “CHR Metz-Thionville”, Ars- Laquenexy, France
  • Marco Campitiello Division of Medical Oncology, “CHR Metz-Thionville”, Ars- Laquenexy, France
  • Francesca Plastino Division of Medical Oncology, “CHR Metz-Thionville”, Ars- Laquenexy, France
  • Christophe Goetz Clinical Research Support Unit, “CHR Metz-Thionville”, Ars-Laquenexy, France
  • Bogdan Margineanu Division of Gynecology, “CHR Metz-Thionville”, Ars-Laquenexy, France
  • Julie Pujois Division of Gynecology, “CHR Metz-Thionville”, Ars-Laquenexy, France
  • Michel Gunther Division of Gynecology, “CHR Metz-Thionville”, Ars-Laquenexy, France
  • Julie Egea Division of Medical Oncology, “CHR Metz-Thionville”, Ars- Laquenexy, France
  • Chloé Wendel Division of Medical Oncology, “CHR Metz-Thionville”, Ars- Laquenexy, France

DOI:

https://doi.org/10.1080/0284186X.2022.2132115

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2022-11-02

How to Cite

Longo, R., Thiebaut, V., Legros, P.-O., Campitiello, M., Plastino, F., Goetz, C., … Wendel, C. (2022). Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study. Acta Oncologica, 61(11), 1394–1399. https://doi.org/10.1080/0284186X.2022.2132115